almagate has been researched along with Corneal Angiogenesis in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Andrade, N; Araújo E Silva, PM; Crispim Ribeiro, J; de Moraes, MO; Fechine, FV; Savio, D | 1 |
| Bock, F; Bucher, F; Cursiefen, C; Hos, D; Lipp, M; Onderka, J; Parthasarathy, A | 1 |
| Bachmann, B; Bock, F; Cursiefen, C; Hos, D; König, Y; Parthasarathy, A; Regenfuss, B | 1 |
| Caglar, Y; Degirmenci, E; Ozdemir, O; Sener, E; Yildiz, DK; Yilmaz, B; Yuksel, N | 1 |
| Adamis, AP; Bradley, J; Calias, P; Cook, G; Dowie, T; Ganley, M; Ju, M; Lange, N; Mailhos, C; Robinson, GS; Shima, DT | 1 |
| Dadgostar, H; Waheed, N | 1 |
2 review(s) available for almagate and Corneal Angiogenesis
| Article | Year |
|---|---|
[Topical inhibition of angiogenesis at the cornea. Safety and efficacy].
Topics: Administration, Topical; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Corneal Neovascularization; Humans; Ophthalmic Solutions; Ranibizumab; Treatment Outcome | 2009 |
The evolving role of vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Clinical Trials, Phase III as Topic; Corneal Neovascularization; Dose-Response Relationship, Drug; Female; Humans; Macular Degeneration; Male; Practice Guidelines as Topic; Ranibizumab; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A | 2008 |
4 other study(ies) available for almagate and Corneal Angiogenesis
| Article | Year |
|---|---|
Effect of Topical Instillation of Pegaptanib Sodium Upon Inflammatory Corneal Neovascularization in Rabbits.
Topics: Administration, Topical; Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Aptamers, Nucleotide; Caustics; Cornea; Corneal Injuries; Corneal Neovascularization; Disease Models, Animal; Inflammation; Instillation, Drug; Male; Neovascularization, Pathologic; Prednisolone; Rabbits; Sodium Hydroxide; Treatment Outcome; Vascular Endothelial Growth Factor A | 2021 |
Blockade of the VEGF isoforms in inflammatory corneal hemangiogenesis and lymphangiogenesis.
Topics: Administration, Topical; Animals; Aptamers, Nucleotide; Cell Proliferation; Corneal Neovascularization; Disease Models, Animal; Endothelial Cells; Female; Fluorescent Antibody Technique, Indirect; Glycoproteins; Lymphangiogenesis; Membrane Transport Proteins; Mice; Mice, Inbred BALB C; Ophthalmic Solutions; Platelet Endothelial Cell Adhesion Molecule-1; Protein Isoforms; Vascular Endothelial Growth Factor A | 2014 |
The impact of subconjuctivally injected EGF and VEGF inhibitors on experimental corneal neovascularization in rat model.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Conjunctiva; Corneal Neovascularization; Disease Models, Animal; Epidermal Growth Factor; Follow-Up Studies; Injections; Male; Ranibizumab; Rats; Rats, Wistar; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Vascular Endothelial Growth Factor A | 2011 |
Simultaneous but not prior inhibition of VEGF165 enhances the efficacy of photodynamic therapy in multiple models of ocular neovascularization.
Topics: Animals; Aptamers, Nucleotide; Choroidal Neovascularization; Chromatography, High Pressure Liquid; Cornea; Corneal Neovascularization; Disease Models, Animal; Drug Therapy, Combination; Male; Mice; Mice, Inbred C57BL; Photochemotherapy; Photosensitizing Agents; Porphyrins; RNA, Messenger; Thromboplastin; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Verteporfin | 2008 |